NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company stated that NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses and is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge.
The next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale.
NanoViricides’ lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds worldwide exclusive perpetual licenses for several drugs targeting various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
For more details, visit the full press release at https://nnw.fm/1ewVT and the company’s newsroom at https://nnw.fm/NNVC.
